Insider Buying: Bausch Health Companies Inc. (NYSE:BHC) Director Acquires 1,029,098 Shares of Stock

Bausch Health Companies Inc. (NYSE:BHC) Director John Paulson acquired 1,029,098 shares of the stock in a transaction dated Wednesday, June 11th. The stock was bought at an average price of $5.24 per share, with a total value of $5,392,473.52. Following the purchase, the director now directly owns 28,222,267 shares in the company, valued at $147,884,679.08. This represents a 3.78% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

John Paulson also recently made the following trade(s):

• On Thursday, June 12th, John Paulson bought 1,005,376 shares of Bausch Health Companies stock. The shares were bought at an average cost of $5.47 per share, for a total transaction of $5,499,406.72.
• On Tuesday, June 10th, John Paulson purchased 754,134 shares of Bausch Health Companies stock. The stock was bought at an average cost of $5.05 per share, with a total value of $3,808,376.70.

Bausch Health Companies Trading Up 9.2%

Bausch Health Companies stock opened at $6.02 on Friday. The firm has a market capitalization of $2.23 billion, a price-to-earnings ratio of -50.12, a price-to-earnings-growth ratio of 0.37 and a beta of 0.28. The firm’s fifty day moving average price is $4.85 and its two-hundred day moving average price is $6.43. Bausch Health Companies Inc. has a 1-year low of $3.96 and a 1-year high of $9.85.

Institutional Investors Weigh In On Bausch Health Companies

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC boosted its stake in Bausch Health Companies by 4,134.7% during the 1st quarter. Acadian Asset Management LLC now owns 673,316 shares of the company’s stock valued at $4,347,000 after purchasing an additional 657,416 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Bausch Health Companies by 3.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock valued at $2,102,000 after purchasing an additional 9,834 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Bausch Health Companies by 97.1% during the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock valued at $6,136,000 after buying an additional 467,270 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in Bausch Health Companies by 1,548.9% during the first quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock worth $162,000 after buying an additional 23,451 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Bausch Health Companies in the 1st quarter valued at $68,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on BHC shares. Wall Street Zen cut shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Saturday, May 10th. Royal Bank of Canada increased their price target on Bausch Health Companies from $8.50 to $10.00 and gave the stock a “sector perform” rating in a report on Friday, May 2nd. One analyst has rated the stock with a sell rating and seven have given a hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.